The phase 1/1b trial included 47 advanced pancreatic ductal adenocarcinoma (PDAC) patients. Of the total patients, 22 were treated with AM0010 alone, while 21 patients were given AM0010 in combination with FOLFOX chemotherapy. Both forms of treatment were observed to be effective; however, grade 3/4 treatment of daily doses of AM0010 correlated with thrombocytopenia, anemia, and neutropenia. When AM0010 was utilized with FOLFOX and on a modified dose schedule, no grade 3/4 adverse events were experienced. Read more . . .
New clinical trial research presented at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer suggests that ARMO BioSciences™ immuno-oncology drug, AM0010, is effective in treating patients with advanced pancreatic cancer.